Mainz Biomed (MYNZ) Competitors $6.07 -0.46 (-7.03%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends MYNZ vs. BLUE, IMRX, HOWL, OPTN, VTVT, KRON, UNCY, ACHL, ALXO, and IMMXShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include bluebird bio (BLUE), Immuneering (IMRX), Werewolf Therapeutics (HOWL), OptiNose (OPTN), vTv Therapeutics (VTVT), Kronos Bio (KRON), Unicycive Therapeutics (UNCY), Achilles Therapeutics (ACHL), ALX Oncology (ALXO), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. bluebird bio Immuneering Werewolf Therapeutics OptiNose vTv Therapeutics Kronos Bio Unicycive Therapeutics Achilles Therapeutics ALX Oncology Immix Biopharma Mainz Biomed (NASDAQ:MYNZ) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership. Is MYNZ or BLUE more profitable? Mainz Biomed has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Mainz Biomed's return on equity of 0.00% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A bluebird bio -565.74%-322.46%-53.17% Does the MarketBeat Community believe in MYNZ or BLUE? bluebird bio received 1026 more outperform votes than Mainz Biomed when rated by MarketBeat users. However, 73.68% of users gave Mainz Biomed an outperform vote while only 70.99% of users gave bluebird bio an outperform vote. CompanyUnderperformOutperformMainz BiomedOutperform Votes1473.68% Underperform Votes526.32% bluebird bioOutperform Votes104070.99% Underperform Votes42529.01% Which has more volatility and risk, MYNZ or BLUE? Mainz Biomed has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Do analysts prefer MYNZ or BLUE? Mainz Biomed currently has a consensus target price of $67.00, suggesting a potential upside of 926.03%. bluebird bio has a consensus target price of $49.14, suggesting a potential upside of 577.83%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts plainly believe Mainz Biomed is more favorable than bluebird bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33bluebird bio 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation and earnings, MYNZ or BLUE? Mainz Biomed has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$900K14.51-$26.30M-$65.60-0.10bluebird bio$29.50M2.39-$211.91M-$37.40-0.19 Does the media refer more to MYNZ or BLUE? In the previous week, Mainz Biomed had 2 more articles in the media than bluebird bio. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for bluebird bio. bluebird bio's average media sentiment score of 0.00 beat Mainz Biomed's score of -0.39 indicating that bluebird bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral bluebird bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in MYNZ or BLUE? 87.4% of bluebird bio shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 1.4% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryMainz Biomed beats bluebird bio on 10 of the 17 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.51M$7.03B$5.86B$9.16BDividend YieldN/A2.90%5.26%4.00%P/E Ratio-0.104.3316.6114.66Price / Sales14.51322.96468.2678.04Price / CashN/A75.4646.0938.87Price / Book0.605.577.465.07Net Income-$26.30M$123.72M$3.19B$222.90M7 Day Performance-11.88%-0.10%0.86%1.23%1 Month Performance23.44%2.72%4.78%4.23%1 Year Performance-84.00%3.56%24.08%20.29% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed3.0225 of 5 stars$6.07-7.0%$67.00+1,003.6%-83.7%$12.20M$900,000.00-0.0930Analyst ForecastBLUEbluebird bio1.7383 of 5 stars$6.10-3.0%$49.14+705.8%-63.1%$59.34M$29.50M-0.16520News CoverageIMRXImmuneering3.4829 of 5 stars$1.87-1.8%$12.20+554.2%-69.0%$57.91M$320,000.00-0.9560Short Interest ↓HOWLWerewolf Therapeutics2.3495 of 5 stars$1.29-5.4%$9.33+625.8%-74.3%$57.71M$19.94M-0.8540Positive NewsOPTNOptiNose4.0459 of 5 stars$5.74-1.3%$16.67+190.6%-70.5%$57.69M$75.67M-1.37190Short Interest ↑VTVTvTv Therapeutics1.4758 of 5 stars$17.98+0.6%$35.00+94.7%+100.0%$57.34M$2.02M-3.979Gap DownKRONKronos Bio3.5653 of 5 stars$0.95-2.1%$1.63+71.1%-1.9%$57.32M$6.29M-0.66100News CoverageUNCYUnicycive Therapeutics3.9343 of 5 stars$0.55-3.3%$5.50+905.5%-46.7%$56.57M$680,000.00-0.569Short Interest ↓Positive NewsHigh Trading VolumeACHLAchilles Therapeutics3.6543 of 5 stars$1.38-0.4%$4.00+190.9%+46.3%$56.51MN/A-0.83250Short Interest ↓News CoverageALXOALX Oncology3.899 of 5 stars$1.06-3.2%$3.05+189.1%-92.4%$55.64MN/A-0.3540Positive NewsIMMXImmix Biopharma3.4105 of 5 stars$2.01flat$7.00+248.3%-29.2%$55.30MN/A-2.369Gap DownHigh Trading Volume Related Companies and Tools Related Companies bluebird bio Alternatives Immuneering Alternatives Werewolf Therapeutics Alternatives OptiNose Alternatives vTv Therapeutics Alternatives Kronos Bio Alternatives Unicycive Therapeutics Alternatives Achilles Therapeutics Alternatives ALX Oncology Alternatives Immix Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYNZ) was last updated on 2/14/2025 by MarketBeat.com Staff From Our Partners*Breaking News!* This Pharma NASDAQ Company and the U.S Army!!! This Little Known NASDAQ Company just released positive results from its drugs that have been undergoing testi...Trading Wire | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s #1 investment during Trump’s termWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.